复方海蛇胶囊联合盐酸多奈哌齐治疗阿尔茨海默病临床观察

目的探讨复方海蛇胶囊(RSC)联合盐酸多奈哌齐治疗阿尔茨海默病(AD)的有效性及安全性。方法 96例AD患者随机分为RSC组30例、盐酸多奈哌齐组32例和联合用药组34例,RSC组给予复方海蛇胶囊口服;盐酸多奈哌齐组给予盐酸多奈哌齐口服;联合用药组同时口服复方海蛇胶囊和盐酸多奈哌齐;连续用药6个月。观察3组患者治疗前后智能状态量表(MMSE)、日常生活能力量表(ADL)、认知次级量表(ADAS-Cog)、痴呆程度评定量表(CDR)以及副反应量表(TESS)评定情况。结果治疗后各组MMSE评分均大于治疗前(P<0.05),ADL、ADAS-Cog、CDR评分均小于治疗前(P均<0.05);3组不良反应发生率比较无显著性差异(P>0.05)。结论复方海蛇胶囊联合盐酸多奈哌齐治疗AD安全、有效,疗效优于单一药物,且不良反应发生率低。

Clinical observation of Reinhartdt and Sea Cucumber Capsule (RSC) combined and donepezil hydrochloride in treatment of alzheimer's disease

Objective It is to approach the efficacy and safety of Reinhartdt and Sea Cucumber Capsule(RSC) co-treatment of donepezil hydrochloride in alzheimer’s disease(AD). Methods Ninety-six patients with AD were randomly divided into RSC group(30 patients),hydrochloric donepezil group(32 patients) and combined treatment group(34 patients).RSC group was treated with RSC by orally;hydrochloride donepezil group was treated with hydrochloric donepezil by orally;combined treatment group also oral RSC and hydrochloric donepezil;continuous medication for six-month-term.The mini-mental state examination(MMSE),activities of daily living scale(ADL),cognitive sub-scale(ADAS-Cog),clinical dementia rating scale(CDR) and side effects scale(TESS) assessment of the situation of three groups were observed. Results ①The MMSE scores in each group after treatment were greater than before,the ADL,ADAS-Cog,CDR score in each group after treatment were less than before treatment,there were significant different(P<0.05).②There were no significant difference in the incidence of adverse in three groups(P>0.05). Conclusion Combination use RSC and donepezil hydrochloride is safe and effective method in treatment of AD,the effect is better than a single drug,and the incidence of adverse reactions is low.